CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia2018 · 5,832 citations
2. 2Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma2020 · 453 citations
3. 3Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report2021 · 216 citations
4. 4CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial2020 · 409 citations
5. 5Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR2023 · 35 citations